IRX-2

BIOLOGICAL4 trials

Sponsors

Brooklyn ImmunoTherapeutics, LLC, University of Southern California, Emory University

Conditions

Cervical Squamous Cell Carcinoma In SituHuman Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Oral CavityStage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

Phase 1

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

WithdrawnNCT03575234

Emory UniversityHuman Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 +2

Start: 2020-07-01End: 2026-01-31Updated: 2019-08-28

Phase 2

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

CompletedNCT00210470

Brooklyn ImmunoTherapeutics, LLCSquamous Cell Carcinoma of the Head and Neck

Start: 2005-07-31End: 2012-03-31Updated: 2020-12-11

IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

CompletedNCT02609386

Brooklyn ImmunoTherapeutics, LLCSquamous Cell Carcinoma of the Oral Cavity

Start: 2016-01-11End: 2022-02-28Updated: 2024-01-30

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

TerminatedNCT03267680

University of Southern CaliforniaCervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion

Start: 2017-11-08End: 2024-03-13Updated: 2025-04-13

Related Papers

Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.

2020-07-2918 citations

Abstract 31: The INSPIRE trial: A randomized trial of neoadjuvant and adjuvant therapy with the IRX-2 regimen in patients with newly diagnosed stage II, III, or IVa squamous cell carcinoma of the oral cavity

Clinical Cancer Research2017-11-30